

# Guillermo J Pons-Estel

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2704951/guillermo-j-pons-estel-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60  
papers

2,344  
citations

21  
h-index

48  
g-index

70  
ext. papers

3,030  
ext. citations

4.6  
avg. IF

4.72  
L-index

#	Paper	IF	Citations
60	Understanding the epidemiology and progression of systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2010</b> , 39, 257-68	5.3	526
59	Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". <i>Journal of Autoimmunity</i> , <b>2009</b> , 32, 240-5	15.5	245
58	Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 1869-73	4.7	206
57	Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 830-9		175
56	Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. <i>Rheumatology</i> , <b>2009</b> , 48, 542-5	3.9	136
55	Epidemiology of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 799-814	5.1	92
54	The antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2017</b> , 76, 10-20	15.5	91
53	Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. <i>Rheumatology</i> , <b>2009</b> , 48, 817-22	3.9	80
52	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1019-23	2.4	64
51	Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 2757-66		64
50	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 2071-2074	2.4	62
49	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, )-Pan-American League of Associations of Rheumatology (PANLAR). <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1549-1557	2.4	57
48	Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 679-84	13.6	53
47	US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 393-4	2.4	49
46	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1137-1146	2.4	49
45	Epidemiology and management of refractory lupus nephritis. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 655-63	13.6	44
44	Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 393-400	4.7	43

43	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. <i>Rheumatology</i> , <b>2012</b> , 51, 1293-8	3.9	39
42	Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 675-83	5.3	34
41	Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 42, 417-23	5.3	24
40	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 134-141	4.7	23
39	Renal involvement in antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , <b>2014</b> , 16, 397	4.9	20
38	Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	17
37	The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort. <i>Lupus</i> , <b>2012</b> , 21, 1397-404	2.6	16
36	Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. <i>Rheumatology</i> , <b>2016</b> , 55, 436-40	3.9	12
35	Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. <i>RMD Open</i> , <b>2019</b> , 5, e000955	5.9	12
34	Lupus in Hispanics: a matter of serious concern. <i>Cleveland Clinic Journal of Medicine</i> , <b>2012</b> , 79, 824-34	2.8	10
33	Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1299-1308	4.1	9
32	Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. <i>Lupus</i> , <b>2020</b> , 29, 1050-1059	2.6	8
31	Applying the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Lupus Criteria to Patients From the LUMINA Cohort: Results From the Multiethnic, Multicenter US Cohort. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1451-1455	4.7	8
30	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	7
29	Remission or low disease activity as a target in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, e3	2.4	6
28	Achievement of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Criteria for Systemic Lupus Erythematosus and Amount of Damage Accrual: Results From a Multiethnic Multicenter Cohort. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1038-1040	4.7	6
27	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 47, 199-203	5.3	5
26	Rheumatoid arthritis in the indigenous qom population of Rosario, Argentina: aggressive and disabling disease with inadequate adherence to treatment in a community-based cohort study. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2323-2330	3.9	4

25	Recambio plasmático en las enfermedades autoinmunes sistémicas. <i>Seminarios De La Fundación Española De Reumatología</i> , <b>2013</b> , 14, 43-50		4
24	Predictors of renal damage in systemic lupus erythematosus patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). <i>RMD Open</i> , <b>2020</b> , 6,	5.9	4
23	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. <i>Nature Reviews Rheumatology</i> , <b>2021</b> ,	8.1	4
22	Skeletal Involvement in Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , <b>2010</b> , 6, 25-31	1.6	3
21	Jaccoud's arthropathy in SLE: findings from a Latin American multiethnic population. <i>Lupus Science and Medicine</i> , <b>2019</b> , 6, e000343	4.6	3
20	Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. <i>Rheumatology International</i> , <b>2021</b> , 1	3.6	2
19	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry		2
18	Health Disparities in Rheumatic Diseases: Understanding Global Challenges in Africa, Europe, Latin America, and Asia and Proposing Strategies for Improvement. <i>Rheumatic Disease Clinics of North America</i> , <b>2021</b> , 47, 119-132	2.4	2
17	Design of an algorithm for the diagnostic approach of patients with joint pain. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 1581-1591	3.9	2
16	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	2
15	A glimpse into the future of systemic lupus erythematosus.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X221086719	3.8	2
14	Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> ,	1.1	1
13	Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus. <i>Revista Colombiana De Reumatología</i> , <b>2021</b> , 28, 21-30	0.2	1
12	Impact of COVID-19 Pandemic on Rheumatology Practice in Latin America. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1616-1622	4.1	1
11	How well do the new classification criteria for SLE perform?. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 7-8	8.1	1
10	Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominousness in SLE" by Whittall Garcia. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
9	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. <i>Lupus</i> , <b>2020</b> , 29, 1140-1145	2.6	0
8	Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort: The LUMINA (Lupus in Minorities: Nature vs. Nurture) Experience (LUMINA LXXXII). <i>Rheumatic Disease Clinics of North America</i> , <b>2021</b> , 47, 55-64	2.4	0

- 7 A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. *Lupus*, **2021**, 961203320988586 2.6 0
- 6 Prognosis in Antiphospholipid Syndrome. *Handbook of Systemic Autoimmune Diseases*, **2017**, 12, 281-294. 0.3
- 5 Is Low Disease Activity Sufficient as a Target in Systemic Lupus Erythematosus? Comment on the Article by Petri et al. *Arthritis and Rheumatology*, **2018**, 70, 2098-2099 9.5
- 4 Epidemiological characteristics and outcomes of SARS-CoV-2 infection in patients with rheumatic diseases: first report from the Argentine SAR-COVID registry **2021**, 7-15
- 3 Musculoskeletal Involvement **2011**, 149-155
- 2 Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. *Rheumatology*, **2020**, 59, e165-e168 3.9
- 1 Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus. *Lupus*, **2021**, 30, 1481-1491 2.6